Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with B...
Intrexon Corporation (NASDAQ: XON) is Powering ...
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with ...
Co-Diagnostics, Inc., a Utah corporation, is a ...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical com...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a c...
Join the National Investor Network and get the latest information with your interests in mind.